On May 29, Tempus AI rose 5.77% in pre-market trading, trading at $54.66/share, with trading volume of $10.82 million.

On the news front, the company announced that its oncology-specific Xt companion diagnostic product (Xt Cdx) has received approval from the U.S. Food and Drug Administration. This critical regulatory milestone enables Tempus AI to migrate its entire DNA-based solid tumor product portfolio to the newly approved platform, representing a significant expansion of its diagnostic capabilities in precision oncology.

In addition to the FDA approval, multiple positive catalysts have converged to support the stock. The company recently upgraded its Tempus Hub physician intelligence platform with a next-generation Agentic AI architecture, integrating large language model capabilities with real-time genomic patient data to provide proactive clinical decision support for oncologists. Financially, the company reported Q1 revenue of $348.1 million, representing 36.1% year-over-year growth that exceeded market expectations, with core diagnostics revenue growing 34.7% year-over-year, providing a solid foundation for continued technology-driven expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)